This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure

This study has been completed.
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: June 30, 2005
Last updated: May 7, 2008
Last verified: October 2006

Patients with end-stage renal failure have a markedly higher mortality because of cardiovascular events in comparison with the normal population. Disorders in the calcium metabolism, such as calcification of the vessel walls, occur very frequently. There are indications that calcium channel blockers are capable of lowering the cardiovascular mortality in patients with end-stage renal failure.

It is intended to carry out a prospective, randomized, double-blind, placebo-controlled, multicenter study in order to find out if the calcium channel blocker amlodipine is able to reduce the mortality of patients with end-stage renal failure.

The investigation will be carried out after suitable explanation and written informed consent in 356 patients aged between 18 and 90 years with end-stage renal failure and chronic haemodialysis treatment. The patients will be randomized to either treatment with amlodipine 10 mg/day or placebo. The occurrence of events will be documented and evaluated prospectively over a period of 30 months.

Condition Intervention Phase
Kidney Failure, Chronic Drug: Amlodipine Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])

Resource links provided by NLM:

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • The primary outcome will be the survival rate. The secondary outcome will be cardiovascular events. [ Time Frame: Prospective: look forward using periodic observations collected predominantly following subject enrollment ]

Enrollment: 356
Study Start Date: January 2002
Study Completion Date: October 2006
Arms Assigned Interventions
Active Comparator: 1
Drug: Amlodipine
Other Name: Placebo
Placebo Comparator: 2
Drug: Placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • End-stage renal disease
  • Hemodialysis
  • Hypertension
  • Written informed consent

Exclusion Criteria:

  • Hypotension of less than 90 mmHg systolic
  • High-grade aortic stenosis
  • Heart failure of NYHA stage III and IV
  • Acute myocardial infarction (within the last 4 weeks)
  • Acute heart failure
  • Known allergy to the medicament amlodipine or other constituents of the medicament
  • Severe disorders of liver function
  • Pregnancy and breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00124969

Charite Campus Benjamin Franklin
Berlin, Germany, 12200
Sponsors and Collaborators
Charite University, Berlin, Germany
Principal Investigator: Martin Tepel, Dr Charite Campus Benjamin Franklin
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00124969     History of Changes
Other Study ID Numbers: ADAM
Study First Received: June 30, 2005
Last Updated: May 7, 2008

Keywords provided by Charite University, Berlin, Germany:
End-stage renal disease, hemodialysis

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on September 20, 2017